nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP1A2—Carmustine—lymphatic system cancer	0.243	0.471	CbGbCtD
Imiquimod—CYP3A4—Cytarabine—lymphatic system cancer	0.087	0.168	CbGbCtD
Imiquimod—CYP3A4—Teniposide—lymphatic system cancer	0.0857	0.166	CbGbCtD
Imiquimod—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0599	0.116	CbGbCtD
Imiquimod—CYP3A4—Vincristine—lymphatic system cancer	0.0413	0.0798	CbGbCtD
Imiquimod—Decreased appetite—Fludarabine—lymphatic system cancer	0.000844	0.00175	CcSEcCtD
Imiquimod—Visual impairment—Carmustine—lymphatic system cancer	0.000842	0.00175	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000838	0.00174	CcSEcCtD
Imiquimod—Fatigue—Fludarabine—lymphatic system cancer	0.000837	0.00173	CcSEcCtD
Imiquimod—Inflammation—Methotrexate—lymphatic system cancer	0.000831	0.00172	CcSEcCtD
Imiquimod—Pain—Fludarabine—lymphatic system cancer	0.00083	0.00172	CcSEcCtD
Imiquimod—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000824	0.00171	CcSEcCtD
Imiquimod—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00082	0.0017	CcSEcCtD
Imiquimod—Urethral disorder—Vincristine—lymphatic system cancer	0.000818	0.00169	CcSEcCtD
Imiquimod—Eye disorder—Carmustine—lymphatic system cancer	0.000817	0.00169	CcSEcCtD
Imiquimod—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000817	0.00169	CcSEcCtD
Imiquimod—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000815	0.00169	CcSEcCtD
Imiquimod—Hypersensitivity—Teniposide—lymphatic system cancer	0.000814	0.00169	CcSEcCtD
Imiquimod—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000813	0.00168	CcSEcCtD
Imiquimod—Flushing—Carmustine—lymphatic system cancer	0.000811	0.00168	CcSEcCtD
Imiquimod—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000809	0.00168	CcSEcCtD
Imiquimod—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000807	0.00167	CcSEcCtD
Imiquimod—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000806	0.00167	CcSEcCtD
Imiquimod—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0008	0.00166	CcSEcCtD
Imiquimod—Asthenia—Teniposide—lymphatic system cancer	0.000792	0.00164	CcSEcCtD
Imiquimod—Malaise—Bleomycin—lymphatic system cancer	0.000786	0.00163	CcSEcCtD
Imiquimod—Pruritus—Teniposide—lymphatic system cancer	0.000781	0.00162	CcSEcCtD
Imiquimod—Arrhythmia—Carmustine—lymphatic system cancer	0.000781	0.00162	CcSEcCtD
Imiquimod—Alopecia—Carmustine—lymphatic system cancer	0.000773	0.0016	CcSEcCtD
Imiquimod—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00077	0.00159	CcSEcCtD
Imiquimod—Body temperature increased—Fludarabine—lymphatic system cancer	0.000767	0.00159	CcSEcCtD
Imiquimod—Mental disorder—Carmustine—lymphatic system cancer	0.000766	0.00159	CcSEcCtD
Imiquimod—Vaginal infection—Methotrexate—lymphatic system cancer	0.000761	0.00158	CcSEcCtD
Imiquimod—Malnutrition—Carmustine—lymphatic system cancer	0.000761	0.00158	CcSEcCtD
Imiquimod—Erythema—Carmustine—lymphatic system cancer	0.000761	0.00158	CcSEcCtD
Imiquimod—Cough—Bleomycin—lymphatic system cancer	0.000761	0.00158	CcSEcCtD
Imiquimod—Angiopathy—Vincristine—lymphatic system cancer	0.000757	0.00157	CcSEcCtD
Imiquimod—Diarrhoea—Teniposide—lymphatic system cancer	0.000756	0.00157	CcSEcCtD
Imiquimod—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000752	0.00156	CcSEcCtD
Imiquimod—Chest pain—Bleomycin—lymphatic system cancer	0.000742	0.00154	CcSEcCtD
Imiquimod—Myalgia—Bleomycin—lymphatic system cancer	0.000742	0.00154	CcSEcCtD
Imiquimod—Alopecia—Vincristine—lymphatic system cancer	0.000737	0.00153	CcSEcCtD
Imiquimod—Back pain—Carmustine—lymphatic system cancer	0.000736	0.00152	CcSEcCtD
Imiquimod—Discomfort—Bleomycin—lymphatic system cancer	0.000733	0.00152	CcSEcCtD
Imiquimod—Mental disorder—Vincristine—lymphatic system cancer	0.000731	0.00151	CcSEcCtD
Imiquimod—Chills—Mitoxantrone—lymphatic system cancer	0.000729	0.00151	CcSEcCtD
Imiquimod—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000726	0.0015	CcSEcCtD
Imiquimod—Alopecia—Mitoxantrone—lymphatic system cancer	0.000718	0.00149	CcSEcCtD
Imiquimod—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.000718	0.00149	CcSEcCtD
Imiquimod—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000715	0.00148	CcSEcCtD
Imiquimod—Oedema—Bleomycin—lymphatic system cancer	0.000712	0.00147	CcSEcCtD
Imiquimod—Erythema—Mitoxantrone—lymphatic system cancer	0.000707	0.00147	CcSEcCtD
Imiquimod—Infection—Bleomycin—lymphatic system cancer	0.000707	0.00146	CcSEcCtD
Imiquimod—Back pain—Vincristine—lymphatic system cancer	0.000703	0.00146	CcSEcCtD
Imiquimod—Vomiting—Teniposide—lymphatic system cancer	0.000702	0.00145	CcSEcCtD
Imiquimod—Agitation—Carmustine—lymphatic system cancer	0.000699	0.00145	CcSEcCtD
Imiquimod—Asthenia—Fludarabine—lymphatic system cancer	0.000696	0.00144	CcSEcCtD
Imiquimod—Rash—Teniposide—lymphatic system cancer	0.000696	0.00144	CcSEcCtD
Imiquimod—Dermatitis—Teniposide—lymphatic system cancer	0.000696	0.00144	CcSEcCtD
Imiquimod—Headache—Teniposide—lymphatic system cancer	0.000692	0.00143	CcSEcCtD
Imiquimod—Pruritus—Fludarabine—lymphatic system cancer	0.000687	0.00142	CcSEcCtD
Imiquimod—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000686	0.00142	CcSEcCtD
Imiquimod—Back pain—Mitoxantrone—lymphatic system cancer	0.000684	0.00142	CcSEcCtD
Imiquimod—Anorexia—Bleomycin—lymphatic system cancer	0.000678	0.00141	CcSEcCtD
Imiquimod—Agitation—Vincristine—lymphatic system cancer	0.000668	0.00138	CcSEcCtD
Imiquimod—Diarrhoea—Fludarabine—lymphatic system cancer	0.000664	0.00138	CcSEcCtD
Imiquimod—Convulsion—Carmustine—lymphatic system cancer	0.000659	0.00137	CcSEcCtD
Imiquimod—Hypertension—Carmustine—lymphatic system cancer	0.000657	0.00136	CcSEcCtD
Imiquimod—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000656	0.00136	CcSEcCtD
Imiquimod—Nausea—Teniposide—lymphatic system cancer	0.000656	0.00136	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000648	0.00134	CcSEcCtD
Imiquimod—Chest pain—Carmustine—lymphatic system cancer	0.000648	0.00134	CcSEcCtD
Imiquimod—Myalgia—Carmustine—lymphatic system cancer	0.000648	0.00134	CcSEcCtD
Imiquimod—Anxiety—Carmustine—lymphatic system cancer	0.000646	0.00134	CcSEcCtD
Imiquimod—Paraesthesia—Bleomycin—lymphatic system cancer	0.000639	0.00132	CcSEcCtD
Imiquimod—Malaise—Mitoxantrone—lymphatic system cancer	0.000638	0.00132	CcSEcCtD
Imiquimod—Dyspnoea—Bleomycin—lymphatic system cancer	0.000634	0.00131	CcSEcCtD
Imiquimod—Convulsion—Vincristine—lymphatic system cancer	0.000629	0.0013	CcSEcCtD
Imiquimod—Hypertension—Vincristine—lymphatic system cancer	0.000627	0.0013	CcSEcCtD
Imiquimod—Oedema—Carmustine—lymphatic system cancer	0.000621	0.00129	CcSEcCtD
Imiquimod—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00062	0.00129	CcSEcCtD
Imiquimod—Decreased appetite—Bleomycin—lymphatic system cancer	0.000619	0.00128	CcSEcCtD
Imiquimod—Myalgia—Vincristine—lymphatic system cancer	0.000618	0.00128	CcSEcCtD
Imiquimod—Cough—Mitoxantrone—lymphatic system cancer	0.000617	0.00128	CcSEcCtD
Imiquimod—Infection—Carmustine—lymphatic system cancer	0.000617	0.00128	CcSEcCtD
Imiquimod—Vomiting—Fludarabine—lymphatic system cancer	0.000617	0.00128	CcSEcCtD
Imiquimod—Convulsion—Mitoxantrone—lymphatic system cancer	0.000613	0.00127	CcSEcCtD
Imiquimod—Rash—Fludarabine—lymphatic system cancer	0.000612	0.00127	CcSEcCtD
Imiquimod—Dermatitis—Fludarabine—lymphatic system cancer	0.000611	0.00127	CcSEcCtD
Imiquimod—Hypertension—Mitoxantrone—lymphatic system cancer	0.000611	0.00127	CcSEcCtD
Imiquimod—Pain—Bleomycin—lymphatic system cancer	0.000608	0.00126	CcSEcCtD
Imiquimod—Headache—Fludarabine—lymphatic system cancer	0.000608	0.00126	CcSEcCtD
Imiquimod—Tachycardia—Carmustine—lymphatic system cancer	0.000606	0.00126	CcSEcCtD
Imiquimod—Chest pain—Mitoxantrone—lymphatic system cancer	0.000602	0.00125	CcSEcCtD
Imiquimod—Myalgia—Mitoxantrone—lymphatic system cancer	0.000602	0.00125	CcSEcCtD
Imiquimod—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000602	0.00125	CcSEcCtD
Imiquimod—Anxiety—Mitoxantrone—lymphatic system cancer	0.0006	0.00124	CcSEcCtD
Imiquimod—Lethargy—Methotrexate—lymphatic system cancer	0.000597	0.00124	CcSEcCtD
Imiquimod—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000597	0.00124	CcSEcCtD
Imiquimod—Discomfort—Mitoxantrone—lymphatic system cancer	0.000595	0.00123	CcSEcCtD
Imiquimod—Oedema—Vincristine—lymphatic system cancer	0.000593	0.00123	CcSEcCtD
Imiquimod—Anorexia—Carmustine—lymphatic system cancer	0.000592	0.00123	CcSEcCtD
Imiquimod—Infection—Vincristine—lymphatic system cancer	0.000589	0.00122	CcSEcCtD
Imiquimod—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000586	0.00121	CcSEcCtD
Imiquimod—Nervous system disorder—Vincristine—lymphatic system cancer	0.000581	0.0012	CcSEcCtD
Imiquimod—Oedema—Mitoxantrone—lymphatic system cancer	0.000577	0.0012	CcSEcCtD
Imiquimod—Nausea—Fludarabine—lymphatic system cancer	0.000576	0.00119	CcSEcCtD
Imiquimod—Infection—Mitoxantrone—lymphatic system cancer	0.000574	0.00119	CcSEcCtD
Imiquimod—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000573	0.00119	CcSEcCtD
Imiquimod—Shock—Mitoxantrone—lymphatic system cancer	0.000568	0.00118	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000566	0.00117	CcSEcCtD
Imiquimod—Urticaria—Bleomycin—lymphatic system cancer	0.000565	0.00117	CcSEcCtD
Imiquimod—Anorexia—Vincristine—lymphatic system cancer	0.000565	0.00117	CcSEcCtD
Imiquimod—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000564	0.00117	CcSEcCtD
Imiquimod—Body temperature increased—Bleomycin—lymphatic system cancer	0.000562	0.00117	CcSEcCtD
Imiquimod—Insomnia—Carmustine—lymphatic system cancer	0.000562	0.00116	CcSEcCtD
Imiquimod—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000561	0.00116	CcSEcCtD
Imiquimod—Irritability—Methotrexate—lymphatic system cancer	0.000559	0.00116	CcSEcCtD
Imiquimod—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000558	0.00116	CcSEcCtD
Imiquimod—Paraesthesia—Carmustine—lymphatic system cancer	0.000558	0.00116	CcSEcCtD
Imiquimod—Dyspnoea—Carmustine—lymphatic system cancer	0.000554	0.00115	CcSEcCtD
Imiquimod—Somnolence—Carmustine—lymphatic system cancer	0.000552	0.00114	CcSEcCtD
Imiquimod—Anorexia—Mitoxantrone—lymphatic system cancer	0.00055	0.00114	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00054	0.00112	CcSEcCtD
Imiquimod—Decreased appetite—Carmustine—lymphatic system cancer	0.00054	0.00112	CcSEcCtD
Imiquimod—Insomnia—Vincristine—lymphatic system cancer	0.000536	0.00111	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000536	0.00111	CcSEcCtD
Imiquimod—Paraesthesia—Vincristine—lymphatic system cancer	0.000532	0.0011	CcSEcCtD
Imiquimod—Pain—Carmustine—lymphatic system cancer	0.000531	0.0011	CcSEcCtD
Imiquimod—Breast disorder—Methotrexate—lymphatic system cancer	0.000529	0.0011	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000526	0.00109	CcSEcCtD
Imiquimod—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000524	0.00109	CcSEcCtD
Imiquimod—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000518	0.00107	CcSEcCtD
Imiquimod—Decreased appetite—Vincristine—lymphatic system cancer	0.000515	0.00107	CcSEcCtD
Imiquimod—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000515	0.00107	CcSEcCtD
Imiquimod—Somnolence—Mitoxantrone—lymphatic system cancer	0.000513	0.00106	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000512	0.00106	CcSEcCtD
Imiquimod—Feeling abnormal—Carmustine—lymphatic system cancer	0.000512	0.00106	CcSEcCtD
Imiquimod—Fatigue—Vincristine—lymphatic system cancer	0.000511	0.00106	CcSEcCtD
Imiquimod—Asthenia—Bleomycin—lymphatic system cancer	0.000511	0.00106	CcSEcCtD
Imiquimod—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000508	0.00105	CcSEcCtD
Imiquimod—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000508	0.00105	CcSEcCtD
Imiquimod—Pain—Vincristine—lymphatic system cancer	0.000507	0.00105	CcSEcCtD
Imiquimod—Pruritus—Bleomycin—lymphatic system cancer	0.000503	0.00104	CcSEcCtD
Imiquimod—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000502	0.00104	CcSEcCtD
Imiquimod—Fatigue—Mitoxantrone—lymphatic system cancer	0.000498	0.00103	CcSEcCtD
Imiquimod—Pain—Mitoxantrone—lymphatic system cancer	0.000494	0.00102	CcSEcCtD
Imiquimod—Abdominal pain—Carmustine—lymphatic system cancer	0.000491	0.00102	CcSEcCtD
Imiquimod—Body temperature increased—Carmustine—lymphatic system cancer	0.000491	0.00102	CcSEcCtD
Imiquimod—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000485	0.001	CcSEcCtD
Imiquimod—Pancytopenia—Methotrexate—lymphatic system cancer	0.00048	0.000995	CcSEcCtD
Imiquimod—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000476	0.000986	CcSEcCtD
Imiquimod—Dysuria—Methotrexate—lymphatic system cancer	0.000473	0.00098	CcSEcCtD
Imiquimod—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000472	0.000978	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00047	0.000974	CcSEcCtD
Imiquimod—Abdominal pain—Vincristine—lymphatic system cancer	0.000469	0.000971	CcSEcCtD
Imiquimod—Body temperature increased—Vincristine—lymphatic system cancer	0.000469	0.000971	CcSEcCtD
Imiquimod—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000466	0.000965	CcSEcCtD
Imiquimod—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000462	0.000957	CcSEcCtD
Imiquimod—Urticaria—Mitoxantrone—lymphatic system cancer	0.000459	0.00095	CcSEcCtD
Imiquimod—Hypersensitivity—Carmustine—lymphatic system cancer	0.000458	0.000948	CcSEcCtD
Imiquimod—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000456	0.000946	CcSEcCtD
Imiquimod—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000456	0.000946	CcSEcCtD
Imiquimod—Vomiting—Bleomycin—lymphatic system cancer	0.000452	0.000937	CcSEcCtD
Imiquimod—Infestation NOS—Methotrexate—lymphatic system cancer	0.000451	0.000934	CcSEcCtD
Imiquimod—Infestation—Methotrexate—lymphatic system cancer	0.000451	0.000934	CcSEcCtD
Imiquimod—Depression—Methotrexate—lymphatic system cancer	0.00045	0.000932	CcSEcCtD
Imiquimod—Rash—Bleomycin—lymphatic system cancer	0.000449	0.000929	CcSEcCtD
Imiquimod—Dermatitis—Bleomycin—lymphatic system cancer	0.000448	0.000929	CcSEcCtD
Imiquimod—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000447	0.000926	CcSEcCtD
Imiquimod—Asthenia—Carmustine—lymphatic system cancer	0.000446	0.000923	CcSEcCtD
Imiquimod—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000438	0.000908	CcSEcCtD
Imiquimod—Hypersensitivity—Vincristine—lymphatic system cancer	0.000437	0.000905	CcSEcCtD
Imiquimod—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000427	0.000884	CcSEcCtD
Imiquimod—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000425	0.000881	CcSEcCtD
Imiquimod—Asthenia—Vincristine—lymphatic system cancer	0.000425	0.000881	CcSEcCtD
Imiquimod—Diarrhoea—Carmustine—lymphatic system cancer	0.000425	0.00088	CcSEcCtD
Imiquimod—Nausea—Bleomycin—lymphatic system cancer	0.000423	0.000876	CcSEcCtD
Imiquimod—Asthenia—Mitoxantrone—lymphatic system cancer	0.000414	0.000858	CcSEcCtD
Imiquimod—Dizziness—Carmustine—lymphatic system cancer	0.000411	0.000851	CcSEcCtD
Imiquimod—Haemoglobin—Methotrexate—lymphatic system cancer	0.000407	0.000843	CcSEcCtD
Imiquimod—Diarrhoea—Vincristine—lymphatic system cancer	0.000406	0.00084	CcSEcCtD
Imiquimod—Haemorrhage—Methotrexate—lymphatic system cancer	0.000405	0.000839	CcSEcCtD
Imiquimod—Pharyngitis—Methotrexate—lymphatic system cancer	0.000402	0.000833	CcSEcCtD
Imiquimod—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0004	0.000828	CcSEcCtD
Imiquimod—Urethral disorder—Methotrexate—lymphatic system cancer	0.000397	0.000822	CcSEcCtD
Imiquimod—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000395	0.000818	CcSEcCtD
Imiquimod—Vomiting—Carmustine—lymphatic system cancer	0.000395	0.000818	CcSEcCtD
Imiquimod—Dizziness—Vincristine—lymphatic system cancer	0.000392	0.000812	CcSEcCtD
Imiquimod—Rash—Carmustine—lymphatic system cancer	0.000392	0.000811	CcSEcCtD
Imiquimod—Dermatitis—Carmustine—lymphatic system cancer	0.000391	0.00081	CcSEcCtD
Imiquimod—Visual impairment—Methotrexate—lymphatic system cancer	0.00039	0.000808	CcSEcCtD
Imiquimod—Headache—Carmustine—lymphatic system cancer	0.000389	0.000806	CcSEcCtD
Imiquimod—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000383	0.000793	CcSEcCtD
Imiquimod—Eye disorder—Methotrexate—lymphatic system cancer	0.000378	0.000784	CcSEcCtD
Imiquimod—Tinnitus—Methotrexate—lymphatic system cancer	0.000378	0.000782	CcSEcCtD
Imiquimod—Vomiting—Vincristine—lymphatic system cancer	0.000377	0.000781	CcSEcCtD
Imiquimod—Rash—Vincristine—lymphatic system cancer	0.000374	0.000774	CcSEcCtD
Imiquimod—Dermatitis—Vincristine—lymphatic system cancer	0.000373	0.000774	CcSEcCtD
Imiquimod—Headache—Vincristine—lymphatic system cancer	0.000371	0.000769	CcSEcCtD
Imiquimod—Nausea—Carmustine—lymphatic system cancer	0.000369	0.000764	CcSEcCtD
Imiquimod—Angiopathy—Methotrexate—lymphatic system cancer	0.000367	0.000761	CcSEcCtD
Imiquimod—Vomiting—Mitoxantrone—lymphatic system cancer	0.000367	0.000761	CcSEcCtD
Imiquimod—Immune system disorder—Methotrexate—lymphatic system cancer	0.000366	0.000758	CcSEcCtD
Imiquimod—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000365	0.000756	CcSEcCtD
Imiquimod—Rash—Mitoxantrone—lymphatic system cancer	0.000364	0.000754	CcSEcCtD
Imiquimod—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000364	0.000753	CcSEcCtD
Imiquimod—Chills—Methotrexate—lymphatic system cancer	0.000363	0.000753	CcSEcCtD
Imiquimod—Headache—Mitoxantrone—lymphatic system cancer	0.000362	0.000749	CcSEcCtD
Imiquimod—Alopecia—Methotrexate—lymphatic system cancer	0.000358	0.000741	CcSEcCtD
Imiquimod—Mental disorder—Methotrexate—lymphatic system cancer	0.000355	0.000735	CcSEcCtD
Imiquimod—Erythema—Methotrexate—lymphatic system cancer	0.000352	0.00073	CcSEcCtD
Imiquimod—Malnutrition—Methotrexate—lymphatic system cancer	0.000352	0.00073	CcSEcCtD
Imiquimod—Nausea—Vincristine—lymphatic system cancer	0.000352	0.00073	CcSEcCtD
Imiquimod—Nausea—Mitoxantrone—lymphatic system cancer	0.000343	0.00071	CcSEcCtD
Imiquimod—Back pain—Methotrexate—lymphatic system cancer	0.000341	0.000706	CcSEcCtD
Imiquimod—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000327	0.000678	CcSEcCtD
Imiquimod—Malaise—Methotrexate—lymphatic system cancer	0.000318	0.000658	CcSEcCtD
Imiquimod—Cough—Methotrexate—lymphatic system cancer	0.000308	0.000637	CcSEcCtD
Imiquimod—Convulsion—Methotrexate—lymphatic system cancer	0.000305	0.000633	CcSEcCtD
Imiquimod—Chest pain—Methotrexate—lymphatic system cancer	0.0003	0.000622	CcSEcCtD
Imiquimod—Arthralgia—Methotrexate—lymphatic system cancer	0.0003	0.000622	CcSEcCtD
Imiquimod—Myalgia—Methotrexate—lymphatic system cancer	0.0003	0.000622	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000298	0.000617	CcSEcCtD
Imiquimod—Discomfort—Methotrexate—lymphatic system cancer	0.000297	0.000614	CcSEcCtD
Imiquimod—Infection—Methotrexate—lymphatic system cancer	0.000286	0.000592	CcSEcCtD
Imiquimod—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000282	0.000584	CcSEcCtD
Imiquimod—Skin disorder—Methotrexate—lymphatic system cancer	0.000279	0.000579	CcSEcCtD
Imiquimod—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000278	0.000576	CcSEcCtD
Imiquimod—Anorexia—Methotrexate—lymphatic system cancer	0.000274	0.000568	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000262	0.000543	CcSEcCtD
Imiquimod—Insomnia—Methotrexate—lymphatic system cancer	0.00026	0.000539	CcSEcCtD
Imiquimod—Paraesthesia—Methotrexate—lymphatic system cancer	0.000258	0.000535	CcSEcCtD
Imiquimod—Dyspnoea—Methotrexate—lymphatic system cancer	0.000256	0.000531	CcSEcCtD
Imiquimod—Somnolence—Methotrexate—lymphatic system cancer	0.000256	0.00053	CcSEcCtD
Imiquimod—Dyspepsia—Methotrexate—lymphatic system cancer	0.000253	0.000525	CcSEcCtD
Imiquimod—Decreased appetite—Methotrexate—lymphatic system cancer	0.00025	0.000518	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000248	0.000515	CcSEcCtD
Imiquimod—Fatigue—Methotrexate—lymphatic system cancer	0.000248	0.000514	CcSEcCtD
Imiquimod—Pain—Methotrexate—lymphatic system cancer	0.000246	0.00051	CcSEcCtD
Imiquimod—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000237	0.000491	CcSEcCtD
Imiquimod—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000235	0.000487	CcSEcCtD
Imiquimod—Urticaria—Methotrexate—lymphatic system cancer	0.000229	0.000473	CcSEcCtD
Imiquimod—Abdominal pain—Methotrexate—lymphatic system cancer	0.000227	0.000471	CcSEcCtD
Imiquimod—Body temperature increased—Methotrexate—lymphatic system cancer	0.000227	0.000471	CcSEcCtD
Imiquimod—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000212	0.000439	CcSEcCtD
Imiquimod—Asthenia—Methotrexate—lymphatic system cancer	0.000206	0.000428	CcSEcCtD
Imiquimod—Pruritus—Methotrexate—lymphatic system cancer	0.000204	0.000422	CcSEcCtD
Imiquimod—Diarrhoea—Methotrexate—lymphatic system cancer	0.000197	0.000408	CcSEcCtD
Imiquimod—Dizziness—Methotrexate—lymphatic system cancer	0.00019	0.000394	CcSEcCtD
Imiquimod—Vomiting—Methotrexate—lymphatic system cancer	0.000183	0.000379	CcSEcCtD
Imiquimod—Rash—Methotrexate—lymphatic system cancer	0.000181	0.000376	CcSEcCtD
Imiquimod—Dermatitis—Methotrexate—lymphatic system cancer	0.000181	0.000375	CcSEcCtD
Imiquimod—Headache—Methotrexate—lymphatic system cancer	0.00018	0.000373	CcSEcCtD
Imiquimod—Nausea—Methotrexate—lymphatic system cancer	0.000171	0.000354	CcSEcCtD
